Investor Area

Home / Investor Area / News / CLINUVEL Newsletter – July 2019
 

CLINUVEL Newsletter – July 2019

 

In this Communiqué we turn our attention to the most recent news communicated to the Company on 31 May by the US Food and Drug Administration (FDA): an extension of the scientific review time for SCENESSE® (afamelanotide 16mg) by three months […]

Download PDF